Free Regulatory Support Offered to Ultra-rare Disease Advocates

Free Regulatory Support Offered to Ultra-rare Disease Advocates

305269

Free Regulatory Support Offered to Ultra-rare Disease Advocates

The clinical research organization MMS Holdings has launched a free program to help advance research and provide regulatory support to ultra-rare disease patient advocacy groups. Most rare diseases are ultra-rare conditions, according to a MMS press release, and require different approaches to navigating statutory requirements for drug development than more common illnesses. MMS has extensive expertise in rare disease programs, having supported more than 12 therapeutic areas in the past decade. Through their pro bono  program, the company…

You must be logged in to read/download the full post.